Hyperhomocysteinemia and Disease-Is 10 μmol/L a Suitable New Threshold Limit?

Area of Science:

• Biochemistry
• Pathophysiology
• Clinical Medicine

Background:

• Hyperhomocysteinemia (HHcy) involves elevated blood homocysteine (Hcy), a toxic amino acid byproduct of methionine metabolism.
• Hcy is managed through remethylation (requiring folate, B12) or trans-sulfuration (requiring B6).
• HHcy is implicated as a risk factor in cardiovascular diseases, neurological disorders, diabetes, and cancer.

Purpose of the Study:

• To review the controversial literature on the normal range of HHcy.
• To evaluate whether slightly elevated Hcy levels (e.g., 7-10 μmol/L) are causative or merely markers of disease.
• To discuss the appropriateness of lowering the diagnostic threshold for HHcy.

Main Methods:

• Literature review of studies investigating HHcy and associated pathologies.
• Analysis of current classifications for mild, moderate, and severe HHcy.
• Examination of the role of vitamins B9, B12, and B6 in Hcy metabolism.

Main Results:

• Current normal ranges for Hcy are debated, with some laboratories using 25 μmol/L as the upper limit.
• Even Hcy levels of 10 μmol/L may contribute to disease development.
• The causative role of mild HHcy in various pathologies remains unclear.

Conclusions:

• The established normal range for HHcy may be too high.
• Lowering the diagnostic threshold for HHcy could improve early detection and intervention.
• Further research is needed to clarify the causal relationship between mild HHcy and disease.